CL report — 2026-08-07

Position	Action
Pullback to $90.71-$91.90 zone	Deploy 50% of new capital
Breakout above $94.25 with volume >5M	Deploy remaining 50% of new capital

Indicator	Value	Signal
close	93.27	—
200-SMA	85.47	bullish
50-SMA	90.71	bullish
10-EMA	92.35	bullish
RSI(14)	55.29	neutral
MACD_line	0.49	bullish
MACD_signal	0.41	—
MACD_histogram	+0.08	neutral
Bollinger_Middle	91.90	—
Bollinger_Upper	94.25	—
Bollinger_Lower	89.55	—
ATR	2.45	—

The Q2 2026 earnings beat was clean with margin expansion; the post-print dip was a gift entry point

EPS of $0.99, +4.5% above consensus (~+4.21% Zacks surprise)
Revenue of $5.36B, +4.9% YoY, in line with consensus
Gross margin expansion to 61.5% (up from 59.4% a year ago)
FY guidance maintained — not cut, not walked down, reaffirmed
Morgan Stanley reiterated thesis of 3–4% organic-sales-growth re-acceleration in H2 2026 and 2027
Stock up +17.5% YTD prior to earnings; dip was profit-taking into the beat, not conviction loss

↩ rebuts: “Bear's claim that 'shares dipped after the print' signals weak conviction”

Post-earnings drift was not institutional accumulation—it's low-conviction price action with no catalyst until Q3 in early October

~$89.88 low on Aug-3 was after the July 31 earnings
Rally to $93.27 on the lowest volume in the visible window (2.72M)
Bar moved higher and the catalyst cupboard is bare until Q3 prints in early October

↩ rebuts: “Post-print dip = gift”

The trailing P/E of 36.7x is a mathematical artifact; forward P/E of 22.7x is in line with consumer-staples peers

Trailing P/E of 36.7x distorted by Q3 2025 non-recurring charge (~ $866M one-time item)
Forward P/E is 22.7x — squarely in line with PG ~22x, KMB ~21x
PEG of 1.79 — fair for defensive compounder with brand moat and EM growth runway
Forward EPS estimate $4.10 vs. TTM EPS $2.54 — Street already normalized for one-time charge
P/B of 315x meaningless: treasury stock $28.9B has compressed book equity to $236M due to aggressive buybacks
DCF intrinsic value above current price per Simply Wall St. model

↩ rebuts: “Bear's claim that P/E of 36.7x signals overvaluation”

Forward P/E of 22.7x requires 61% YoY EPS recovery that comes from lapping the Q3 2025 charge, not organic growth; clean-year P/E is ~29-31x

Forward P/E of 22.7x requires EPS to hit $4.10
TTM EPS is $2.54
~61% YoY EPS growth from TTM to forward
Underlying TTM run-rate (excluding Q3 2025) is ~$3.00–$3.20 in EPS
At $93.27 is a forward P/E closer to 29–31x
P&G trades around 22x on clean earnings
Kimberly-Clark around 21x
Dividend yield 2.28% vs 10-year Treasury ~4.2%
10-year Treasury yields ~85% more than CL's dividend

↩ rebuts: “Forward P/E 22.7x is cheap”

The stock is not 'extended' — it is a slow-grind compounder sitting below its 52-week high with all MAs stacked bullish

CL's 5-year total shareholder return is only ~30.8% (barely 6% annualized)
Stock still trading below 52-week high of $99.33 — buying at $93.27 is 6% below that high
Price is +9.1% above the 200-SMA, +2.8% above the 50-SMA, +1.0% above the 10-EMA
All three MAs are stacked bullish: 10-EMA > 50-SMA > 200-SMA
200-SMA rising (84.99 → 85.47); 50-SMA rising (88.88 → 90.71)
Dividend yield of 2.28% beats 10-year Treasury's ~4.2% when accounting for growth and safety

↩ rebuts: “Bear's claim that +17.5% YTD means the stock is 'extended'”

CL compounded at ~5.5% annualized over 5 years, underperforming the S&P 500's high single digits to low teens; stock is 6% below 52-week high and bounded since Q2

~5.5% annualized for five years including dividends
S&P 500 total return over same period was high single digits to low teens
Stock is 6% below its 52-week high
Rallied from $89.88 to $93.27 (+3.8% move)
Bounded since Q2

↩ rebuts: “5-yr TSR is steady”

US/North America softness is a regional headwind, not a business model failure — 80% of revenue is growing

North America is ~20% of CL's revenue base
The other ~80% is Latin America, EMEA, and Asia-Pacific — exactly where MS sees 3–4% organic growth re-acceleration
Q2 2026 global revenue still grew +4.9% YoY to $5.36B despite North America softness
Colgate holds 40%+ global toothpaste share and continues taking share from private label
LatAm and EM are secular tailwind stories: rising middle class, urbanization, oral care penetration <50% in many EM markets, Hill's Pet Nutrition pet humanization trend
Gross margins expanded 210 basis points YoY even in 'soft' North America — pricing power machine

↩ rebuts: “Bear's claim that US category softness and elevated competition signals structural weakness”

North America (20-25% of sales) is the highest-margin region with a 25%+ operating margin in US oral care; softness is a margin story, not just a revenue story

North America for Colgate runs roughly 20–25% of consolidated sales
US oral care business at 25%+ operating margin
Hill's Pet Nutrition (a North America-heavy franchise, ~$3B+ in revenue alone) lives almost entirely in developed markets
LatAm growth at 5–7% in local currency is great, but a 1–2% volume decline in the US oral care business at 25%+ operating margin is a bigger P&L hit than a comparable percentage gain in EM at half the margin

↩ rebuts: “NA is only 20% of sales”

Hormuz/Iran war risk is already priced in; Q2 2026 proved CL can navigate cost-pressure regimes with margin expansion

Q2 2026 gross margin: 61.5% (up from 59.4% in Q2 2025)
That's 210 basis points of expansion despite Hormuz premium, higher oil-derived inputs (palm oil, surfactants, packaging resins), higher freight
Colgate has demonstrated pricing power and productivity program that absorbs input inflation

↩ rebuts: “Bear's claim that Hormuz/Iran war scenario creates input cost shock”

Q2 ended June 30 before the worst of the Hormuz escalation in late July and early August; Q3 income statements will absorb the next wave of commodity cost pressures

Q2 ended June 30, 2026
Strait of Hormuz disruption and US embassy evacuations intensified in late July and early August
Gulf oil exports still ~40% below pre-war levels
Companies raising prices on packaging, freight, beer, paint due to commodity/transport costs
Palm oil derivatives spot up double-digits in July
Packaging resins tied to oil
Ocean freight rates firming

↩ rebuts: “Hormuz is priced in”

In a higher-for-longer rate environment, CL's defensive yield is the most attractive risk-adjusted trade in equities

CL dividend yield: 2.28%, growing every year for decades
Beta: 0.33 — a third of S&P 500's volatility
10-year T-Bond: ~4.2%, with embedded duration risk if Fed cuts unexpectedly
Recession odds at just 8% and falling (-4.5pp week-over-week)
Polymarket: 86% probability of no Fed cuts in 2026
If Fed surprises dovish (14% probability), CL gets multiple-expansion tailwind on top of dividend yield story
CL doesn't need multiple expansion to deliver — it delivers via dividend growth, buybacks, and organic volume

↩ rebuts: “Bear's claim that higher-for-longer rates cap the multiple”

In a higher-for-longer rate environment with no Fed cuts, multiples stay capped and the dividend doesn't even cover the risk-free rate; income investors should buy Treasuries

86% probability of no Fed cuts in 2026 (Polymarket)
Fed funds at 5%+
Mid-single-digit organic growth at CL
CL dividend 2.28% doesn't cover the risk-free rate of ~4.2%
Without cuts, multiples stay capped

↩ rebuts: “Higher rates = defensive bid”

Technical indicators signal healthy pullback within a trend, not a reversal — the path of least resistance is up

MACD line (0.49) still above signal (0.41); histogram compressing from +0.34 to +0.08 but still positive — healthy consolidation, not reversal
Real tops have MACD crossing below signal — that hasn't happened
Volume thin on Aug-7 (2.72M) is quiet accumulation signature in defensive name, not distribution
Aug-3 low at $89.88 was bought on declining volume — professional accumulation on quiet tape
Upper Bollinger band at $94.25 is breakout trigger; confirmed daily close above it on volume >5M opens measured move to $97–$98 (February 2026 swing highs)
RSI(14) at 55.29 — neutral-bullish with room to run
Lower Bollinger: $89.55 (immediate floor); 50-SMA: $90.71 (medium-term support)
ATR: $2.45 supports $3.50–$4.50 stop (1.5–1.8× ATR) keeping risk-per-trade at ~2%

↩ rebuts: “Bear's claims that MACD histogram compressing, volume is light, and price at upper Bollinger signal topping”

MACD histogram compressing from +0.34 to +0.08 while price made new local highs is negative momentum divergence—a 'healthy pullback' requires price consolidating sideways, not making new highs

MACD histogram compressing from +0.34 to +0.08
Price higher ($93.27 now vs ~$91 area in early July when histogram was +0.34)
Classic negative momentum divergence
Next leg lower on histogram will be bearish MACD crossover (line crossing below signal)
One or two sessions of weakness away from it

↩ rebuts: “MACD compressing = healthy pullback”

2.72M volume on Aug-7 was ~30% below average (4M+ shares on normal sessions); a breakout attempt on 30% below-average volume is not a confirmed breakout

2.72M on Aug-7
Normal sessions trade 4M+ shares
~30% below average
Low-conviction push
Breakout not confirmed

↩ rebuts: “Light volume = accumulation”

Price at upper Bollinger band ($94.25) is a 2-standard-deviation move above the mean where supply historically overwhelms demand, especially with decelerating momentum and light volume

Price pressing $94.25 (upper band)
Upper Bollinger band is a 2-standard-deviation move above the mean
6% distance to the prior swing high that's already failed once

↩ rebuts: “Price at upper Bollinger breakout”

CL is funding buybacks with rising LT debt at 5%+ while paying a 2.28% dividend—a negative-carry trade that destroys book equity and leaves the company vulnerable in credit-stress scenarios

Long-term debt up $680M YoY ($7.14B → $7.82B)
Cash up $150M
Stockholders' equity collapsed 66% YoY ($702M → $236M)
ROE of 267% is a warning sign that the company is starving itself of reinvestment capital
CL paying ~5%+ on incremental debt to buy back stock yielding 2.28%
Negative-carry trade

↩ rebuts: “Buyback floor”

Morgan Stanley's 3-4% organic growth view is one bank's view, not consensus; if organic comes in at 3% instead of 4%, and FX turns against EM, EPS lands at $3.85–$3.95—a 4-6% miss to consensus of $4.10

Morgan Stanley sees 3–4% organic growth re-acceleration in H2 2026 and 2027
Base grew 4.9% YoY in Q2 largely on pricing, not volume
Street consensus on FY2027 EPS is ~$4.10
If organic comes in at 3% instead of 4% and FX turns against EM, EPS lands at $3.85–$3.95
4–6% miss to consensus

↩ rebuts: “MS sees 3-4% organic”

CL is already up 17.5% YTD on defensive rotation that's mature; risk-on tape drives money into cyclicals, tech, AI, and small caps, not defensives that lag in risk-on and lead in risk-off

CL up 17.5% YTD
The rotation into defensives is mature
Where is the next leg of defensive bid coming from?

↩ rebuts: “Macro tailwind argument”

Trade Plan

Bull vs Bear

Bull case

Risk Debate

Analyst Reports

Technicals

Re-evaluate at

Bear case

Fundamentals

Catalysts

Sentiment